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Background: Tissue acidosis is effective in causing chronic muscle pain. However, how muscle nociceptors
contribute to the transition from acute to chronic pain is largely unknown.
Results: Here we showed that a single intramuscular acid injection induced a priming effect on muscle nociceptors
of mice. The primed muscle nociceptors were plastic and permitted the development of long-lasting chronic
hyperalgesia induced by a second acid insult. The plastic changes of muscle nociceptors were modality-specific and
required the activation of acid-sensing ion channel 3 (ASIC3) or transient receptor potential cation channel V1
(TRPV1). Activation of ASIC3 was associated with increased activity of tetrodotoxin (TTX)-sensitive voltage-gated
sodium channels but not protein kinase Cε (PKCε) in isolectin B4 (IB4)-negative muscle nociceptors. In contrast,
increased activity of TTX-resistant voltage-gated sodium channels with ASIC3 or TRPV1 activation in NaV1.8-positive
muscle nociceptors was required for the development of chronic hyperalgesia. Accordingly, compared to wild type
mice, NaV1.8-null mice showed briefer acid-induced hyperalgesia (5 days vs. >27 days).
Conclusion: ASIC3 activation may manifest a new type of nociceptor priming in IB4-negative muscle nociceptors.
The activation of ASIC3 and TRPV1 as well as enhanced NaV1.8 activity are essential for the development of
long-lasting hyperalgesia in acid-induced, chronic, widespread muscle pain.
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Chronic muscle pain is a significant clinical problem affect-
ing many people [1]. Although both peripheral and central
sensitizations are believed involved in the transition from
acute to chronic muscle pain, the underlying mechanism
is not well understood [2-4]. An emerging hypothesis of
hyperalgesic priming proposed by Jon Levine is that the
transition might involve neural plasticity in primary affer-
ent nociceptors, whereby an acute noxious stimulation
can trigger long-lasting hypersensitivity of nociceptors
to subsequent insults [5]. The hyperalgesic priming
phenomenon occurs in a specific subset of nociceptors* Correspondence: chih@ibms.sinica.edu.tw
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unless otherwise stated.that bind isolectin B4 (IB4) and requires increased activity
of tetrodotoxin (TTX)-resistant sodium channels and a
switch in intracellular signaling pathways from protein
kinase A to the epsilon isoform of protein kinase C (PKCε)
in response to the same stimulus [6-8].
Tissue acidosis in muscles related to ischemia and
inflammation has a profound effect on the initiation
and development of chronic muscle pain [9,10]. Proton-
sensing ion channels, such as acid-sensing ion channel 3
(ASIC3) and transient receptor potential cation channel
V1 (TRPV1), are involved in activating muscle nociceptors
and inducing the central sensitization that occurs in ani-
mal models of chronic muscle pain [11-13]. To probe how
acid triggers chronic muscle pain, Sluka and colleagues
developed a rodent model of chronic muscle pain induced
by acid saline injected twice, 5 days apart, to the gastro-
cnemius muscle (GM) on one side of mice or rats [14,15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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algesia in both hind paws that diminishes in 24 h. The sec-
ond acid injection 5 days later to the same side induces
long-lasting referred hyperalgesia. Furthermore, although
the dual acid injections are unilateral in the same site, the
hyperalgesic effects are bilateral and the induction of chronic
widespread pain shifts the autonomic balance to sympa-
thetic predominance and decreases baroreflex sensitivity,
which are related to findings in humans with chronic
widespread pain or fibromyalgia [16].
The requirement of dual acid injections to evoke chronic
muscle pain implies a hyperalgesic priming of muscle
nociceptors after the first acid injection. Although proton-
sensing ion channels are implicated in the initiation of
hyperalgesia induced by intramuscular injections, only
ASIC3 was confirmed to play an essential and sufficient
role in triggering the acid-induced chronic muscle pain
[15,17]. However, how ASIC3 induces the hyperalgesic
priming is not known and whether TRPV1 is involved in
the acid-induced, chronic, widespread pain is not clear.
In this study, we aimed to reveal the molecular mechan-
ism underlying the transition from acute to chronic muscle
pain in the acid-induced, chronic, widespread pain model.
We tested how ASIC3 and/or TRPV1 activation affects the
duration of the hyperalgesic priming state and the chronic
pain state induced by dual intramuscular acid insults.
Results
Neural subgroups of acid-sensitive muscle afferent
DRG neurons
Although the expression of ASIC3 and its functional im-
plications have been characterized in muscle nociceptors,
the response of TRPV1-expressing muscle nociceptors to
acid is poorly addressed. We first analyzed acid-induced
currents in muscle afferent dorsal root ganglion (DRG)
neurons and determined the neural populations of ASIC3-
and TRPV1-expressing muscle nociceptors by inhibition
with salicylic acid (SA, ASIC3 antagonist) and capsazepine
(TRPV1 antagonist) [18,19]. Whole-cell patch clamp
recording revealed that most of the small- to medium-sized
(20–40 μm in diameter) muscle afferent DRG neurons
expressed acid-induced inward currents (34/40), including
17.5% (7/40) ASIC3-like currents, 10% (4/40) TRPV1-like
currents, and 7.5% (3/40) ASIC3-/TRPV1-like currents
(Figure 1).
Involvement of TRPV1 and ASIC3 in the establishment of
hyperalgesic priming
We next examined whether deletion or inhibition of
TRPV1 would affect the intramuscular-acid–induced
hyperalgesia. Trpv1−/− mice showed transient hyperalgesia
after the first and second acid injections spaced 5 days
apart but failed to show long-lasting hyperalgesia after
the second acid injection as did Trpv1+/+ mice (Figure 2Aand B). Interestingly, inhibiting TRPV1 by co-injection of
acid and capsazepine at the first injection or at the second
injection did not affect the development of long-lasting
hyperalgesia (Figure 2C and D). Only co-injection of acid
with capsazepine in both injections abolished the develop-
ment of long-lasting hyperalgesia and produced an exact
phenocopy of the Trpv1 gene deletion (Figure 2E). These
results suggest a role for TRPV1 in mediating the hyper-
algesic priming and hypersensitivity of primed nocicep-
tors. Although TRPV1 inhibition at the first acid injection
did not abolish the hyperalgesic priming, it shortened
the duration of the long-lasting hyperalgesia induced
by the second acid-alone injection (Figure 2F and G).
TRPV1 activation at the first acid injection may be required
for establishing nociceptor priming, which is important
for maintaining long-lasting hyperalgesia induced by a
second acid insult.
In contrast, Asic3−/− mice showed neither transient
nor long-lasting hyperalgesia with dual intramuscular
acid injections spaced 5 days apart (Figure 3A, B). We
next used a pharmacological approach to probe the role of
ASIC3 in the hyperalgesic priming. With co-injection of
acid with APETx2 (2 or 20 pmole), a selective ASIC3 antag-
onist [20], at the first injection, the transient hyperalgesia
was not evoked; a second acid injection on day 5 evoked
only transient hyperalgesia, which suggests that the
nociceptors were in an unprimed state (Figure 3C). Co-
injection of acid with APETx2 (20 pmole) at the second
injection induced transient but not long-lasting hyperalge-
sia (Figure 3D). Therefore, the primed nociceptors require
ASIC3 activation for developing chronic hyperalgesia in
the dual acid-injection scheme.
The duration of hyperalgesic priming
Although we did not observe nociceptor priming on day
5 when APETx2 inhibited ASIC3 at the first acid injection,
we cannot exclude that a shorter duration of hyperalgesic
priming was evoked with TRPV1. Thus, we tested whether
activating TRPV1 only (by inhibiting ASIC3 with APETx2)
could still contribute to short-term hyperalgesic priming
in muscle nociceptors, if the dual acid injections were ad-
ministered less than 5 days apart. With the dual acid injec-
tions administered 1 day apart, the second acid injection
produced a robust long-lasting hyperalgesia for more than
12 days as compared with the basal responses before the
second injection; however, the hyperalgesia lasted for
7 days with co-injection of acid with APETx2 (20 pmole)
at the first injection (Figure 3E and F). The next-day
acid-injection–induced hyperalgesia could still last for
3 days even with a higher dose of APETx2 (200 pmole)
(Figure 3G). Interestingly, with co-injection of acid and
APETx2 (20 pmole) and capsazepine, the response was
totally blunted to the next-day acid injection (Figure 3H).
Thus, TRPV1 and ASIC3 are the major proton-sensing
Figure 1 Representative traces of 5 acid-evoked current types in small- to medium-sized muscle afferent dorsal root ganglion (DRG)
neurons. (A) In acid-sensing ion channel 3 (ASIC3)-negative, transient receptor potential cation channel V1 (TRPV1)-negative neurons,
acid-induced currents were resistant to 500 μM salicylic acid (SA, a selective blocker for ASIC3) and 10 μM capsazepine (CZP, a selective blocker
for TRPV1). (B) In ASIC3-positive, TRPV1-negative neurons, acid-induced currents were inhibited by SA but not by CZP. (C) In ASIC3-negative,
TRPV1-positive neurons, acid-induced currents were inhibited by CZP but not by SA. (D) In ASIC3-positive, TRPV1-positive neurons, acid-induced
currents were inhibited by both SA and CZP. (E) In a small subset of neurons, no acid-induced current was obtained. Numbers are number of
neurons to total recorded neurons.
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induced hyperalgesic priming and hyperalgesia. TRPV1
could play a central role together with ASIC3 in the acid-
induced hyperalgesic priming. We further validated this
concept by finding that co-injection of acid with capsaze-
pine shortened the duration of the long-lasting hyperalge-
sia induced by the second acid injection (Figure 3I).
We further tested the contribution of activating only
TRPV1 or ASIC3 in the dual acid injections spaced 2 days
apart (Figure 3J-L), and the results were very similar to the
dual acid injections spaced 1 day apart. Thus, both ASIC3
and TRPV1 channels may contribute to the acid-induced
hyperalgesic priming of muscle nociceptors, but both have
a different contribution to the duration of the first acidinjection-induced nociceptor priming and the maintenance
of long-lasting hyperalgesia induced by the second acid
injection (Table 1).
ASIC3 and TRPV1 activation enhanced TTX-sensitive
(TTXs) and TTX-resistant (TTXr) voltage-gated sodium
current (INaV) in muscle nociceptors
We next probed whether the ASIC3- and TRPV1-mediated
hyperalgesic priming in muscle nociceptors resulted from
INaV as seen in inflammation-induced hyperalgesic priming
[7]. We analyzed the peak amplitudes of INaV in 2 types
of muscle afferent DRG neurons, TTXr and non-TTXr
neurons, on the basis of existence of a TTXr current
(Figure 4A). We thus compared the INaV in muscle afferent
Figure 2 Involvement of peripheral TRPV1 in intramuscular-acid–induced mechanical hyperalgesia. The withdrawal responses of mouse
hind paws to a 0.2-mN bending force in Trpv1+/+ and Trpv1−/− mice before and after intramuscular acid injection. (A) Trpv1+/+ and (B) Trpv1−/−
mice were injected with pH 4.0 saline on days 0 and 5. (C) Co-injection of acid with capsazepine (1 nmole) at the first injection did not affect the
development of hyperalgesia to the repeated acid injection in wild-type (WT) mice. (D) Capsazepine (1 nmole) at the second acid injection did
not affect the development of hyperalgesia. (E) Capsazepine (1 nmole) at both acid injections prevented the development of long-lasting
hyperalgesia. (F) Dual acid injections induced long-lasting hyperalgesia more than 19 days. (G) Coinjection of acid with capsazepine (1 nmole) at
day 0 resulted in short-lasting hyperalgesia, for 7 days. Black arrows indicate when mice received the intramuscular acid injection. Red arrows
indicate when mice received the co-injection of acid with capsazepine. B, baseline on day 0; D, day. *P < 0.05 compared with the response before
the second acid injection.
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jection of pH 7.4 saline or acid (pH 4.0 saline) with or
without APETx2 or capsazepine (Figure 4B). As compared
with pH 7.4 saline injection, at 2 days after acid injec-
tion, non-TTXr GM DRG neurons showed significantly
enhanced TTXs INaV. However, co-injection of acid and
APETx2 or capsazepine did not reverse the acid-induced
increase in TTXs INaV (Figure 4C). In contrast, although
TTXr GM DRG neurons did not differ in the TTXs com-
ponent of INaV with treatment, TTXr INaV was significantly
increased with acid injection, and inhibition of ASIC3
or TRPV1 effectively reversed the acid-induced effect
(Figure 4D). In non-TTXr GM DRG neurons, enhanced
TTXs INaV was maintained with acid only or co-injection
with capsazepine but not co-injection with APETx2 5 days
after acid injection (Figure 4E), which suggests that inhib-
ition of ASIC3 would shorten the duration of hyperalgesic
priming. In TTXr GM DRG neurons, the enhanced TTXr
INaV was still maintained with acid-only treatment 5 days
after acid injection (Figure 4F). Taken together, the acid-
induced plastic changes of nociceptors occurred in both
non-TTXr and TTXr GM DRG neurons, with a significant
increase of INaV in both muscle nociceptor populations.Subtypes of ASIC3-expressing muscle nociceptors
To better understand the cell-type–specific effects of
ASIC3 and TRPV1 activation on TTXr INaV, we used
genetic tools to analyze how these proton-sensing ion
channels related to NaV1.8 expression and whether
they were expressed in IB4-positive neurons that are
essential for hyperalgesic priming. We first examined
the co-expression of NaV1.8 and IB4 in muscle afferent
DRG neurons from mice that carry a NaV1.8-Cre allele to
drive the GFP reporter allele (Figure 5). Among 1,004
muscle afferent DRG neurons (from 3 mice), 317 (31.6%)
were NaV1.8-positive. Among the NaV1.8-positive muscle
afferent DRG neurons, 64% (203/317) were co-localized
with IB4, and the other 36% (114/317) were not. Because
NaV1.8 contributes the most to TTXr INaV in DRG
neurons, we next analyzed the acid-induced currents
in NaV1.8-expressing GM DRG neurons. Before electro-
physiological recordings, cultured DRG neurons were
stained with IB4-DyLight to determine whether the
NaV1.8-expressing GM DRG neurons were IB4-positive
or -negative. We categorized the muscle afferent DRG
neurons into 2 cell-sized groups, small-sized (20–30 μm
in diameter) and medium-sized (30–40 μm in diameter),
Figure 3 Contribution of ASIC3 and TRPV1 to hyperalgesic priming in muscle nociceptors. (A,B) Dual intramuscular acid injections
induced chronic hyperalgesia in Asic3+/+ mice but did not induce hyperalgesia in Asic3−/− mice. (C) Co-injection of acid with APETx2 (20 pmole)
abolished the acid-induced transient hyperalgesia and prevented the development of long-lasting hyperalgesia with the second acid injection on
day 5 in wild-type mice. (D) APETx2 (20 pmole) at the second acid injection produced only transient hyperalgesia in wild-type mice. (E-I) Mice
received dual acid injections 1 day apart. The hyperalgesia lasted more than 12 days (E). Mice developed shorter terms of hyperalgesia up to 7
or 3 days with the first acid injection combined with 20 pmole (F) or 200 pmole (G) APETx2, respectively. (H) Co-injection of 20 pmole APETx2
and 1 nmole capsazepine in the first acid injection abolished the development of long-lasting hyperalgesia with the second acid injection.
(I) Co-injection of acid and 1 nmole capsazepine shortened the second acid-induced hyperalgesia to 9 days. (J-L) Mice received dual acid injections
2 days apart. No coinjection (J), co-injection of acid and 20 pmole APETx2 (K), and co-injection of acid and 1 nmole capsazepine (L) had different
effects on hyperalgesia duration induced by the second acid injection. Black arrows indicate when mice received intramuscular acid injections. Green,
red, and purple arrows indicate when mice received the co-injection of acid with APETx2, capsazepine, and APETx2 combined with capsazepine
respectively. B, baseline on day 0; D, day. *P < 0.05 compared with the response before the second acid injection.
Table 1 Effect of acid-sensing ion channel 3 (ASIC3) and
transient receptor potential cation channel V1 (TRPV1)
inhibition on maintenance of hyperalgesia induced by dual
acid injections
First injection
Maintenance of hyperalgesia induced
by the second acid injection on
Day 1 Day 2 Day 5
Acid with APETx2
7 days (20 pmole) 6 days
(20 pmole)
4 hr
(20 pmole)3 days (200 pmole)
Acid with capsazepine 9 days 9 days 7 days
Acid with vehicle >12 days >12 days >12 days
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were smaller than 30 μm in diameter. Whole-cell patch
clamp recording revealed that ASIC3 was expressed in 30%
(9/30) of NaV1.8-positive and IB4-negative medium-sized
GM DRG neurons but not in IB4-positive small-sized GM
DRG neurons (Table 2). This result echoes our previous
finding of acid-induced enhanced TTXr-INaV found only in
medium-sized GM DRG neurons but not in small-sized
GM DRG neurons [21]. We thus further examined the
NaV1.8-negative medium-sized GM DRG neurons and
found that 23% (6/26) expressed an ASIC3-like current.
Interestingly, a high frequency of ASIC3-expressing neu-
rons also expressed TRPV1 (Table 2). The expression of
Figure 4 The effect of ASIC3 and TRPV1 signaling on voltage-gated sodium currents (INaV) in the acid-induced muscle pain model.
(A) Representative current traces show tetrodotoxin (TTX)-sensitive and -resistant (TTXr) INaV evoked in medium-sized gastrocnemius muscle (GM)
DRG neurons. (B) The experimental design of INaV analysis on muscle afferent DRG neurons. Mice were injected with 20 μL pH 7.4 saline, pH 4.0
saline, pH 4.0 saline with 20 pmole APETx2, or pH 4.0 saline with 1 nmole capsazepine. Effect of intramuscular acid injections on INaV in (C) non-TTXr
and (D) TTXr GM DRG neurons isolated 2 days after acid injection. Effect of intramuscular acid injection on INaV in (E) non-TTXr and (F) TTXr GM DRG
neurons isolated 5 days after acid injection. Data are mean ± SEM; *P < 0.05 and **P < 0.01 vs. pH 7.4; #P < 0.05 vs. pH4.0; $ P = 0.053 vs. pH4.0.
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sized GM DRG neurons supports that ASIC3 activation
could contribute to the acid-enhanced INaV in both TTXr
and non-TTXr GM DRG neurons and that APETx2 could
significantly attenuate the acid-enhanced INaV.
Roles of NaV1.8 and PKCε in acid-induced
chronic hyperalgesia
Although enhanced TTXr INaV was observed in PKCε-
dependent nociceptor priming [7], we found no association
of acid-induced nociceptor priming and ASIC3- or TRPV1-
enhanced TTXr INaV (Figures 3 and 4). To determine the
biological meaning of the acid-enhanced TTXr INaV, we
probed the effect of NaV1.8 deletion on the intramuscular
acid-induced hyperalgesia. With dual acid injections spaced
2 or 5 days apart, NaV1.8
−/− mice showed transient hyper-
algesia after the first acid injection but not long-lasting
hyperalgesia after the second acid injection (Figure 6A, B).
The second acid injection induced hyperalgesia that lastedfor only 2 to 4 days in NaV1.8
−/− mice. These data suggest
a role for NaV1.8 in establishing nociceptor priming, which
is important for maintaining the long-lasting hyperalgesia
induced by repeat acid injections, whereas the plastic
changes of NaV1.8 did not contribute to setting the dur-
ation of priming. Furthermore, an NaV1.8-selecitve blocker,
A-803467, had analgesic effects on wild-type mice that had
developed chronic hyperalgesia induced by second acid in-
jection, which suggests that NaV1.8 is involved in maintain-
ing the acid-induced chronic hyperalgesia (Figure 6C, D).
Finally, we examined whether the acid-induced hyper-
algesic priming depends on the activation of PKCε as
seen in inflammatory pain models [5]. With the dual acid-
injection model, we intramuscularly injected mice with the
cell-permeable PKCε inhibitor peptide (TAT-PKCεI) at 5 h
after the first acid injection (Figure 7A, B) or 3 min before
the second acid injection (Figure 7C, D). In both cases, the
inhibition of PKCε activity did not affect the acid-induced
long-lasting hyperalgesia. To further validate that PKCε
Figure 5 Expression of NaV1.8 and isolectin B4 (IB4) in muscle afferent DRG neurons labeled with retrograde tracing of flourogold in
NaV1.8
+/−-Cre mice carrying the CAG-STOPfloxed-EGFP allele. (A) NaV1.8-positive, IB4-negative neurons represented 11.5% of total muscle
afferent DRG neurons. (B) NaV1.8-negtive, IB4-positive neurons represented 4.7% of total muscle afferent DRG neurons. (C) NaV1.8-positive,
IB4-positive neurons represented 20.0% total muscle afferent DRG neurons. (D) NaV1.8-negative, IB4-negative neurons represented 63.7% of total
muscle afferent DRG neurons. Arrows indicate the neurons of the cell type described at the right panel.
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hyperalgesic priming, we intramuscularly injected mice
with a general PKC inhibitor, BIM, at 5 h after the first acid
injection or 3 min before the second acid injection. Again,
BIM had no effect on the acid-induced long-lasting hyper-
algesia (Figure 7E-H). Therefore, activation of PKCε is not
required in the acid-induced hyperalgesic priming.
Discussion
Acid-induced hyperalgesic priming is PKCε-independent
in muscle nociceptors
Accumulating evidence has suggested that the hyperalgesic
priming of nociceptors is essential for the transition from
acute to chronic pain states in many perplexing chronicpain conditions that are stress-related or neuropathic
[5,22,23]. In inflammatory pain models, the hyperalge-
sic priming occurs exclusively in IB4-positive primary
afferent nociceptors and depends on a switch in intracellu-
lar signaling pathways from PKA to PKCε [6,8,24]. The
PKCε-dependent hyperalgesic priming is also present in
vibration-induced muscle pain and chemotherapy-induced
neuropathic pain and thus may constitute a general cellular
basis for nociceptor plasticity in chronic pain [22,23]. Here
we systematically examined the effect of the modality of the
noxious acid insult on the duration of the hyperalgesia
priming and the development of chronic hyperalgesia with
a fixed, second acid injection. ASIC3 and TRPV1 were the
major proton sensors responsible for the acid-induced
Table 2 Electrophysiological characterization of ASIC3
and TRPV1 expression in subsets of muscle afferent
dorsal root ganglion neurons
No. of acid-sensitive neurons in subsets









(30–40 μm) (30–40 μm) (<30 μm)
ASIC3(+), TRPV1(−) 1 (4%) 4 (13%) 0
ASIC3(+), TRPV1(+) 5 (19%) 5 (17%) 0
ASIC3(−), TRPV1(+) 5 (19%) 2 (7%) 10 (40%)
ASIC3(−), TRPV1(−) 13 (50%) 14 (47%) 6 (24%)
No current 2 (8%) 5 (17%) 9 (36%)
Total 26 30 25
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manifests a new type of hyperalgesic priming mediated by
ion channels (but not by PKCε) in the non-inflammatory
model of chronic muscle pain (Figure 8).
Acid-induced muscle nociceptor priming is modality-
dependent mediated via ASIC3 and/or TRPV1
ASIC3 is responsible for the acid-induced transient hyper-
algesia and hyperalgesic priming, and the developmentFigure 6 Involvement of NaV1.8 in acid-induced chronic muscle pain.
short-term hyperalgesia (2–4 days) in NaV1.8
−/− mice. (C, D) Analgesic effec
have developed chronic hyperalgesia induced by dual intramuscular acid inje
injected immediately after the baseline response (control) had been obtained
receive intraperitoneal injection of vehicle or A-803467 respectively. *P < 0.05of chronic hyperalgesia to repeat acid injections. TRPV1
plays a minor but important role in the acid-induced
hyperalgesic priming and the development of chronic
hyperalgesia (Figure 8). The inhibitory effects of APETx2
and capsazepine on INaV enhancement were consistent
with their effects on the duration of hyperalgesic priming
and the maintenance of the chronic hyperalgesia induced
by the second acid injection in the dual acid-injection
model. Of note, inhibiting ASIC3 abolished the enhanced
INaV in non-TTXr GM DRG neurons on day 5 but not
day 2, so the lack of INaV enhancement was associated
with no chronic hyperalgesia induced by the second
acid injection in mice receiving APETx2 5 days previ-
ous. In contrast, the TTXr GM DRG neurons seemed
to have little role in setting the priming state for future
acid insult. Instead, the enhanced TTXr INaV in GM
DRG neurons was inhibited by both APETx2 and
capsazepine, which was associated with the effects of
both drugs on shortening the hyperalgesia phase in-
duced by the second acid injection (Table 1). Taken
together, acid-induced hyperalgesic priming seems to
be modality-dependent. ASIC3- and TRPV1-mediated
nociceptor priming has differential effects on the de-
velopment and maintenance of chronic hyperalgesia
induced by a repeated acid insult.(A, B) Dual acid injections spaced 2 (A) or 5 (B) days apart induced
t of NaV1.8-selective blocker A-803467 was tested at 3 days after mice
ction spaced 5 days apart. The A-803467 (70 mg/kg, i.p.) or vehicle was
. B, baseline on day 0; D, day. Blue and red arrows indicate the time mice
compared with the response before the second acid injection or control.
Figure 7 Protein kinase Cε (PKCε) does not contribute to nociceptor priming in acid-induced muscle pain model. (A-D) Effect of PKCε
inhibitor peptide (V1–2, EAVSLKPT) on acid-induced hyperalgesia. Intramuscular injection of neutral saline (A, C) or 1 nmole PKCε inhibitor peptide
(B, D) 5 hr after the first acid injection (A, B) or 3 min before the second acid injection (C, D) did not affect the development of hyperalgesia.
(E-H) Effect of a general PKC inhibitor (BIM) on acid-induced hyperalgesia. Intramuscular injection of neutral saline (E, G) or 9.7 nmole BIM (F, H)
5 hr after the first acid injection (E, F) or 3 min before the second acid injection (G, H) did not affect the development of hyperalgesia. Black
arrows indicate when mice received the intramuscular acid injection. B, baseline on day 0; D, day. *P < 0.05 compared with the response before
the second acid injection.
Chen et al. Molecular Pain 2014, 10:40 Page 9 of 15
http://www.molecularpain.com/content/10/1/40The duration of priming and the establishment of
priming are mechanistically different
Our current study addresses neural subgroups involved
in the acid-induced nociceptor priming and also differ-
ent aspects of priming: (1) the duration of priming that
determines how long the primed state can stay and (2)
the establishment of priming that determines how long
the second acid injection-induced hyperalgesia can be
maintained (Figure 8). Mechanistically, in NaV1.8-negative
muscle nociceptors, the activation of ASIC3 contributes to
acid-induced transient hyperalgesia and enhanced TTX-s
INaV as well as the duration of priming; TRPV1 might play
a minor but essential role in setting the duration of prim-
ing. In contrast, in NaV1.8-positive muscle nociceptors,
both ASIC3 and TRPV1 contribute to the acid-enhanced
TTXr INaV, which is required for the establishment of
priming that permits the development and maintenance
of long-term hyperalgesia induced by a second acid
insult. Accordingly, although mice lacking NaV1.8 still
showed hyperalgesic priming, they could develop hyper-
algesia for only 2 to 4 days in the dual acid-injection
model (Figure 6).ASIC3, TRPV1, and NaV1.8 play different roles in muscle
pain associated with acidosis
Accumulating evidence has revealed that most metabo-
nociceptive muscle afferent neurons contain ASIC3 and/
or TRPV1, so both channels might be responsible for the
muscle pain associated with acidosis [11,12,25]. Our study
echoes this finding and further suggests a role for ASIC3
and TRPV1 in acid-induced hyperalgesic priming in muscle
nociceptors. Although ASIC3 plays an important role in
hyperalgesic priming and triggering chronic hyperalgesia, a
recent study showed that ASIC3 is not involved in main-
taining hyperalgesia in the dual acid-injection model [26].
Accordingly, the ASIC3-selective antagonists (e.g., APETx2)
work in pre-emptive analgesia (a treatment that is initiated
before injury or noxious stimulation to reduce sensitization)
in rodent models of acid-induced chronic widespread pain,
postoperative pain, and inflammatory pain but not in ani-
mals with chronic pain [27-30].
However, the role of TRPV1 in maintaining the acid-
induced chronic hyperalgesia is still not known. Recent
studies revealed that TRPV1 plays a role in the develop-
ment of heat hypersensitivity after muscle inflammation
Figure 8 A schematic model of ion channel-mediated hyperalgesic priming in muscle nociceptors. ASIC3 and TRPV1 are expressed in
different subsets of muscle nociceptors with or without NaV1.8 expression. In NaV1.8-negative muscle nociceptors, ASIC3 is the major acid sensor
responsible for acid-induced transient hyperalgesia and the duration of hyperalgesic priming; TRPV1 may play a minor but essential role in the
nociceptor priming. In NaV1.8-positive muscle nociceptors, both ASIC3 and TRPV1 contribute to the acid-enhanced TTXr INaV, which is required for
the establishment of priming that permits the development and maintenance of long-term hyperalgesia induced by a second acid insult. ASIC3
and TRPV1 are expressed alone or together, but ASIC3 is exclusively expressed in non-IB4 muscle nociceptors.
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stream of NGF and GDNF [31,32]. TRPV1 is a pronocicep-
tive polymodal receptor sensing for vanilloid compounds
(e.g., capsaicin), noxious heat (>43°C) and low pH
(<5.9) and could act as the final substrate of multiple
inflammatory mediators that operate via distinct intracellu-
lar signaling pathways such as PKC [33]. PKCε-mediated
potentiation of TRPV1 in DRG neurons contributes to
heat hyperalgesia in rats [34]. However, PKC signaling is
probably not involved in acid-induced TRPV1 activation
in muscle nociceptors.
In contrast, the involvement of TTXr sodium channels
in maintaining chronic hyperalgesia sheds light on the
clinical use of the channel blocker. NaV1.8 is clearly not
involved in setting the duration of hyperalgesic priming.
Instead, the increased TTXr sodium current after the first
acid injection was related to the long-lasting hyperalgesia
after the second acid injection. In mice lacking NaV1.8,
dual acid-injection–induced hyperalgesia was shortened to
2 to 4 days as compared with more than 19 days in wild-type mice. Accordingly, the NaV1.8-selective antagonist
(A-803467) and general sodium channel blockers such as
mexiletine or lamotrigine (37.5 mg/kg, intraperitoneally)
have analgesic effects on the acid-induced, chronic, wide-
spread pain model [35]. Thus, a selective sodium channel
blocker (e.g., A-803467) might be a good choice to treat
chronic muscle pain associated with recurrent ischemic
insults [36]. Since the expression of NaV1.8 is restricted to
the peripheral nervous system, the selective antago-
nists would reduce the risk of side effects on the cen-
tral nervous system [37,38].
One concern with the study may be the selectivity of
APETx2; a recent study revealed that APETx2 inhibited
NaV1.8 currents of DRG neurons with an IC50 of 2.6 μM
in vitro [39]. In the current study, we used a total of 20
pmole APETx2 (in 20 μL acid saline with a concentration
of 1 μM APETx2) to inhibit the acid-induced nociceptor
priming; with this dose, APETx2 should mostly inhibit
homomeric ASIC3 channels or partially heteromeric
ASIC3 channels and had little inhibitory effect on NaV1.8
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first acid injection) was enough to abolish the second
acid injection (on day 5) inducing chronic hyperalgesia
(data not shown), which further confirmed the involvement
of ASIC3 (but not Nav1.8) in the nociceptor priming.
Nevertheless, a more selective ASIC3 antagonist without an
inhibitory effect on NaV1.8 will be helpful to clearly distin-
guish the roles of ASIC3 and NaV1.8 in the acid-induced
nociceptor priming.Is other acid-induced signaling involved in the
acid-induced hyperalgesic priming?
Apart from NaV1.8, other cellular signaling might be
involved in initiating the hyperalgesia in the first few
days after the second acid insult or in regulating the in-
creased activity of NaV1.8. For instance, we previously
showed that substance P-mediated antinociceptive sig-
naling in muscle nociceptors is diminished after repeat
acid injection [21]. Intramuscular acid stimulation triggers
the release of substance P from muscle nociceptors, which
acts on NK1 receptors and activates M-type potassium via
a G-protein–independent but Src-kinase–dependent man-
ner. As well, proton-sensing G-protein–coupled receptors
(e.g., G2A, GPR4, OGR1, TDAG8) and MrgprB4 are
abundantly expressed in ASIC3-positive nociceptors and
may contribute to the development of the intramuscular
acid-induced hyperalgesia [40-42]. Moreover, other
acid-induced responses in muscle afferent DRG neurons
express neither ASIC3 nor TRPV1 (Figure 1 and Table 2)
[43-46]. Future studies of muscle nociceptor-specific
acid signaling would bring new insights into the molecular
mechanism of chronic muscle pain and new opportunities
for effective treatment.
Recent studies show that IB4-positive muscle nociceptors
are responsible for chronic muscle pain triggered by
acute inflammation (e.g., intramuscular carrageenan or glial
cell-derived neurotrophic factor) or ergonomic intervention
(e.g., eccentric exercise or vibration) [47,48]. Although
NaV1.8 is largely expressed in IB4-positive muscle noci-
ceptors, ASIC3 is exclusively expressed in non-IB4 muscle
afferent DRG neurons with or without NaV1.8 expression
(Table 2). However, we cannot exclude the role of
IB4-positive muscle nociceptors in the development
of long-lasting hyperalgesia in the dual acid-injection
model, because many IB4- and NaV1.8-positive muscle
nociceptors express TRPV1, which also contributes to
the enhanced TTXr INaV and the chronic hyperalgesia
induced by the second acid injection. Because TRPV1
channels are expressed in both IB4-positive and -negative
muscle nociceptors, further studies should explore the
differential roles of these 2 TRPV1-expressing muscle
nociceptors in the pathogenesis of acid-induced chronic
widespread pain.Does the acid-induced priming effect occur in the central
nervous system?
The priming hypothesis aims to describe a new mode of
neuroplastic change in primary afferent nociceptors, in
which basal nociceptive thresholds are still normal but
nociceptors are sensitized against exposure to algogens
or sensitizing agents [5]. However, whether the priming
effect occurs in the central nervous system is not known.
In the acid-induced chronic widespread pain model, the
first acid injection induces a transient hyperalgesia that
declines in 24 h (basal nociceptive threshold is back to
normal in von Frey assay), but a priming effect lasts for
5 days, annotated by an increase in INaV in muscle noci-
ceptors and a potential to develop chronic hyperalgesia
in response to future acid insults. Although we have
focused on the plastic changes of noccieptors in the
primed state (1–5 days after the first acid injection),
we cannot exclude possible plastic changes in the cen-
tral nervous system after the first intramuscular acid
injection.
The bilateral effect from a unilateral intramuscular in-
jection suggests the involvement of central sensitization.
Evidence has shown the unilateral dual acid injections
induce activation of the cAMP pathway in the spinal cord,
ERK activation in the anterior nucleus of paraventricular
thalamus (PVA), and plastic changes in capsular central
amygdaloid neurons [49-51]. However, no study has
addressed whether a single acid injection can induce a
plastic change (or the priming effect) in the central ner-
vous system. We have not been able to demonstrate a
plastic change in capsular central amygdaloid neurons
in the primed state (Cheng SJ and Chen CC, unpublished
observation). Interestingly, our previous studies showed
that blockade of CaV3.2 T-type Ca
2+ channel signaling or
ERK activation in the PVA at 15 min before the second
acid injection can prevent the chronic hyperalgesia, which
suggests a possible central role of the PVA in the primed
state [50]. Furthermore, acid can only induce transient
hyperalgesia but not chronic hyperalgesia in mice lacking
CaV3.2. Further studies of CaV3.2–dependent synaptic
plasticity of PVA circuits in the primed state may shed
light on the central control of the transition from acute
to chronic pain.
Conclusions
In conclusion, our data manifest a new type of nociceptor
priming mechanism that involves activation of ASIC3
and TRPV1 in muscle nociceptors and requires the devel-
opment of acid-induced, chronic, widespread muscle pain.
We highlight the role of NaV1.8 in developing and main-
taining the chronic pain and rule out the involvement of
IB4-positive nociceptors and PKCε signaling in the tran-
sition from acute to chronic pain. These results will be
clinically useful, because we provide a new opportunity
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muscle pain resulting from re-current acid insults possibly




We used adult (8- to 12-wk-old) male C57/BL6 mice. All
procedures followed the US Guide for the Care and Use
of Laboratory Animals (National Academy of Sciences,
Washington DC) and were approved by the Institutional
Animal Care and Use Committee of Academia Sinica.
Asic3−/− and NaV1.8
−/−-Cre mice were generated and geno-
typed as described [53,54]. Trpv1−/− mice were purchased
from the Jackson Lab (Bar Harbor, ME). All null-mutant
mice were backcrossed to C57BL6 mice for at least 10 gen-
erations to establish a congenic strain. Congenic Asic3−/−,
NaV1.8
−/−-Cre, and Trpv1−/− mice were offspring of Asic3+/−,
NaV1.8
+/−-Cre, and Trpv1+/− intercrosses respectively.
To identify NaV1.8-positive dorsal root ganglion (DRG)
neurons, NaV1.8
−/−-Cre mice were crossed with mice
carrying a CAG-CAT-enhanced green fluorescent protein
(CAG-CAT-EGFP) reporter allele with a stop-floxed seg-
ment inserted upstream of the EGFP (CAG-STOPfloxed-
EGFP) [55].
Behavioral assays
Mice received 2 injections, spaced 1–5 days apart, into
the GM, of 20 μL acid saline (pH 4.0) with or without
capsazepine (1 nmole), APETx2 (2, 20, or 200 pmole),
or capsazepine (1 nmole) with APETx2 (20 pmole)
(Figure 9A-C). The acid saline was prepared in 10 mM
2-[N-morpholino]ethanesulfonic acid and adjusted to
pH 4.0 with 1 N NaOH. To test the effect of NaV1.8 on
the maintenance of chronic hyperalgesia, the selective
channel blocker A-803467 (Tocris, Avonmouth, UK)
was dosed in 70 mg/kg intraperitoneally at 3 days after
the mice have received dual acid injection (Figure 9D).
To test the effect of PKCε, the PKCε inhibitor peptide
(V1–2, EAVSLKPT) was conjugated with protein trans-
duction domain of TAT protein (CYGRKKRRQRRR-
CEAVSLKPT, TAT-PKCεI) and was kindly provided from
KAI pharmaceuticals (South San Francisco, CA). We
injected 20 μL of the cell-permeable TAT-PKCεI (50 μM
in pH 7.4 saline) or a general PKC inhibitor BIM (485 μM
in pH 7.4 saline, purchased from Cayman Chemical,
Ann Arbor, Michigan) into the GM 5 h after the first
acid injection or 3 min before the second injection
(Figure 9E). Mechanical hyperalgesia was assessed as
described [21]. Briefly, a 0.2 mN von Frey filament was
applied to the plantar surface of both hind paws. A
positive response was defined as foot lifting when the
von Frey filament was applied. For each paw, the filament
was applied 5 times at 30-s intervals. The experimenterswere blinded to the experimental manipulations and/or
mouse genotypes.
DRG primary culture
To retrograde-trace muscle afferent DRG neurons, mice
were anesthetized with 2% isoflurane and injected with
10 μL of 4% (wt/vol) fluorogold into the GM of both
legs for 5 to 8 days. Lumbar DRG neurons were isolated,
dissociated and cultured as described [21]. After seeding,
DRG neurons were maintained in a 5% (vol/vol) CO2
incubator at 37°C and used for patch-clamp recording
within 30 h. IB4-positive neurons were determined by
staining with IB4-DyLight 594 (2.5 μg/mL in solution
containing 0.1 mM MgCl2, CaCl2, and MnCl2; Vector Lab)
for 2 min immediately before the recording. To visualize
NaV1.8-expressing GM DRG neurons, DRG neurons
were isolated from NaV1.8
+/−-Cre mice carrying the
CAG-STOPfloxed-EGFP allele.
Whole-cell patch-clamp recording
Whole-cell patch clamp recordings of muscle afferent
DRG neurons involved use of an Axopatch MultiClamp
700B (Axon Instruments). Neurons with membrane
potential > −40 mV were not accepted. The bridge was
balanced in the current clamp mode and the series re-
sistance was compensated 70% in voltage clamp mode
with Axopatch 700B compensation circuitry. All DRG
neuron recordings were performed at room temperature
and were completed within 30 h after plating. The record-
ing electrodes had a resistance of 1–5 MΩ when filled
with an internal solution containing (in mM) 100 KCl, 2
Na2-ATP, 0.3 Na3-GTP, 10 EGTA, 5 MgCl2, and 40 Hepes,
adjusted to pH 7.4 with KOH. Recording cells were super-
fused in artificial cerebrospinal fluid (ACSF) containing
(in mM) 130 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose,
and 20 Hepes, adjusted to pH 7.4 with NaOH. Osmolarity
was adjusted to approximately 300 mOsm. ACSF was con-
trolled by gravitational force. The acidic ACSF was titrated
to pH 5.0 by 2-[N-morpholino]ethanesulfonic acid (MES).
Salicylic acid (SA) was prepared from a 1-M stock solution
(in 100% ethanol) to a final concentration of 500 μM in
ACSF. Capsazepine was prepared from a 20 mM stock
solution (in 100% ethanol) to a final concentration of
10 μM in ACSF. TTX was prepared from a 100-μM
stock solution to a final concentration of 200 nM in
ACSF. Capsazepine and TTX were purchased from
Torcis (Avonmouth, UK) and APETx2 was from Alomone
(Jerusalem, Israel). Otherwise, drugs were from Sigma
Chemicals (St. Louis, MO).
Acid-induced currents
First, a 1-ms 2 nA current step was used to evoke an action
potential (AP). An AP with inflected falling phase indicates
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Figure 9 The temporal sequence of five experimental groups in the dual acid injection model. (A) Experimental design to probe the role
of ASIC3 and TRPV1 in acid-induced hyperalgesia in the dual acid-injection scheme spaced 5 days apart. (B,C) Experimental design to test the role
of ASIC3 and TRPV1 in acid-induced hyperalgesic priming when the second acid injection was given at day 1 (B) or day 2 (C). (D) Experimental
design to test the analgesic effect of NaV1.8 blocker on the acid-induced chronic widespread pain. (E) Experimental designs to test the role of
PKCε on acid-induced hyperalgesic priming.
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figuration, inflections were determined by differentiation of
AP. To obtain acid-induced currents, the acidic ACSF was
applied through a glass pipette 50 μm from the neuron and
via gravity controlled by aVC-6 six-channel valve controller
(Warner Instruments). Acidic ACSF was applied for 4 s
in 30-s intervals. After 3 applications, SA (500 μM)
was bath-applied to examine whether the acid-induced
current was inhibited. SA-containing bath was then re-
placed with normal ACSF for another 3 min. Next,
capsazepine was bath-applied to examine whether the
acid-induced current was inhibited. ASIC3-expressing
neurons were defined when the acid-induced current
was inhibited by SA [18]; TRPV1-expressing neurons
were defined when the acid-induced current was inhib-
ited by capsazepine [19].
Voltage-gated sodium currents
Mice were injected first with 4% (wt/vol) fluorogold into
GM and 3 days later with acidic saline (pH 4.0, 20 μL)
alone or with 1 nmole capsazepine or 20 pmole APETx2.Mice were killed 2 or 5 days later, and DRG neurons
were isolated and cultured as stated above and used to
study voltage-gated sodium currents. Medium-sized DRG
neurons with cell diameters 30–40 μm were selected for
recording. The internal solution contained (in mM) 10
NaCl, 110 CsCl, 20 tetraethylammonium-chloride, 2.5
MgCl2, 5 EGTA, 3 Mg
2+-ATP, and 5 Hepes, adjusted
to pH 7.0 with CsOH. The external solution contained
(in mM) 100 NaCl, 5 CsCl, 30 tetraethylammonium-
chloride, 1.8 CaCl2, 1 MgCl2, 0.1 CdCl2, 25 glucose, 5
4-aminopyridine, and 5 Hepes, adjusted to pH 7.4
with HCl. Osmolarity was adjusted to 300 mOsm with
glucose. The INaV was evoked by a 30-ms test pulse
at −30 mV from a holding potential of −80 mV. For
TTXr sodium currents, recordings were performed
in external solution containing 200 nM TTX.
Immunohistochemistry
To examine the expression of NaV1.8 and IB4 in muscle
afferent DRG neurons, NaV1.8
+/−-Cre mice carrying the
CAG-STOPfloxed-EGFP allele were injected with 4% (wt/vol)
Chen et al. Molecular Pain 2014, 10:40 Page 14 of 15
http://www.molecularpain.com/content/10/1/40fluorogold into the GM 5 days before DRG isolation.
Lumbar DRGs (L3-5) were isolated and fixed with 4%
paraformaldehyde (in pH 7.4 phosphate buffered saline
[PBS]) at 4°C for 2 h. Post-fixed tissues were placed in
20% sucrose at 4°C overnight, then embedded in OCT
and rapidly frozen with use of dry ice and stored at −80°C.
Frozen sections 12-μm thick were cut on a cryostat
and mounted on glass slides. Slides were fixed with 4%
paraformaldehyde at 4°C for 10 min, then incubated
with blocking solution containing 1% bovine serum al-
bumin, 0.1% Triton X-100, 0.02% sodium azide in PBS
for 1 h at room temperature. After a PBS wash, the
slides were stained with IB4-DyLight 594 for 30 min at
room temperature.
Data analysis
Data for INaV are presented as mean ± SEM and were
analyzed by use of Origin 8.0 (OriginLab). One-way
ANOVA and then Fisher’s least significant difference
post-hoc test were used to compare differences between
groups. The Mann–Whitney U test was used to compare
withdrawal responses to von Frey filament application in
mice before and after acid injection. P < 0.05 was consid-
ered statistically significant.
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